[ORGANIZATION]
beremagene geperpavec
Featured in 1 tracked story · first seen
Situations
AIFA rare disease treatment approvals in Italy
2 clusters · 22 sources · last updated
Latest: Italy approves reimbursement for mirdametinib to treat neurofibromatosis type 1
The Italian Medicines Agency (AIFA) has expanded the reimbursement of several specialized therapies through the National Health Service. On October 29, 2026, AIFA approved reimbursement for beremagene geperpavec (Vyjuv